These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35642117)

  • 21. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.
    Katsiki N; Kazakos K; Triposkiadis F
    Expert Opin Pharmacother; 2022 Dec; 23(17):1957-1974. PubMed ID: 36322877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of dual inhibition of DPP4 and SGLT2 on tacrolimus-induced diabetes mellitus and nephrotoxicity in a rat model.
    Ko EJ; Shin YJ; Cui S; Lim SW; Chung BH; Yang CW
    Am J Transplant; 2022 Jun; 22(6):1537-1549. PubMed ID: 35294797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis.
    Chikata Y; Iwata H; Miyosawa K; Koike T; Yasuda H; Funamizu T; Doi S; Endo H; Wada H; Naito R; Ogita M; Dohi T; Kasai T; Isoda K; Okazaki S; Miyauchi K; Minamino T
    Sci Rep; 2022 Mar; 12(1):5129. PubMed ID: 35332212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis.
    Evans M; Kuodi P; Akunna CJ; McCreedy N; Donsmark M; Ren H; Nnaji CA
    Diab Vasc Dis Res; 2023; 20(6):14791641231221740. PubMed ID: 38111352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment.
    Yin R; Xu Y; Wang X; Yang L; Zhao D
    Molecules; 2022 May; 27(10):. PubMed ID: 35630534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
    Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
    Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidence.
    Pala L; Rotella CM
    J Diabetes Res; 2013; 2013():590456. PubMed ID: 23853775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
    Garber AJ
    Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
    Kim SC; Schneeweiss S; Glynn RJ; Doherty M; Goldfine AB; Solomon DH
    Ann Rheum Dis; 2015 Nov; 74(11):1968-75. PubMed ID: 24919467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
    Gilbert MP; Pratley RE
    Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
    Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
    Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials.
    Zhong J; Gong Q; Goud A; Srinivasamaharaj S; Rajagopalan S
    J Diabetes Res; 2015; 2015():606031. PubMed ID: 26075284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study.
    Lee KA; Jin HY; Kim YJ; Kim SS; Cho EH; Park TS
    Medicine (Baltimore); 2022 Feb; 101(8):e28823. PubMed ID: 35212277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?
    Paolisso G; Monami M; Marfella R; Rizzo MR; Mannucci E
    Adv Ther; 2012 Mar; 29(3):218-33. PubMed ID: 22411425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.